Skip to main navigation Skip to search Skip to main content

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

  • Joan R. Tymon-Rosario
  • , Paola Manara
  • , Diego D. Manavella
  • , Stefania Bellone
  • , Tobias Max Philipp Hartwich
  • , Justin Harold
  • , Yang Yang-Hartwich
  • , Margherita Zipponi
  • , Jungmin Choi
  • , Kyungjo Jeong
  • , Levent Mutlu
  • , Kevin Yang
  • , Gary Altwerger
  • , Gulden Menderes
  • , Elena Ratner
  • , Gloria S. Huang
  • , Mitchell Clark
  • , Vaagn Andikyan
  • , Masoud Azodi
  • , Peter E. Schwartz
    • Ludmil B. Alexandrov, Alessandro D. Santin*
*Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    23   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor'. Together they form a unique fingerprint.
    Sort by

    Keyphrases

    Medicine and Dentistry